10 Analysts Have This To Say About Madrigal Pharmaceuticals
10 analysts have expressed a variety of opinions on Madrigal Pharmaceuticals (NASDAQ:MDGL) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 4 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 2 | 1 | 0 | 0 | 0 |
| 3M Ago | 3 | 2 | 1 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $635.2, a high estimate of $900.00, and a low estimate of $445.00. This upward trend is apparent, with the current average reflecting a 23.29% increase from the previous average price target of $515.20.
Investigating Analyst Ratings: An Elaborate Study
The analysis of recent analyst actions sheds light on the perception of Madrigal Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jonathan Wolleben | Citizens | Raises | Market Outperform | $745.00 | $527.00 |
| Yasmeen Rahimi | Piper Sandler | Raises | Overweight | $900.00 | $540.00 |
| William Woods | B. Riley Securities | Raises | Buy | $670.00 | $560.00 |
| Andrew S. Fein | HC Wainwright & Co. | Raises | Buy | $620.00 | $568.00 |
| Jay Olson | Oppenheimer | Raises | Outperform | $650.00 | $600.00 |
| Srikripa Devarakonda | Truist Securities | Raises | Buy | $640.00 | $580.00 |
| Edward Nash | Canaccord Genuity | Raises | Buy | $587.00 | $526.00 |
| Andrew S. Fein | HC Wainwright & Co. | Raises | Buy | $568.00 | $500.00 |
| Jonathan Wolleben | Citizens | Raises | Market Outperform | $527.00 | $485.00 |
| Alexandria Hammond | B of A Securities | Raises | Neutral | $445.00 | $266.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Madrigal Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Madrigal Pharmaceuticals compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Madrigal Pharmaceuticals's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Madrigal Pharmaceuticals's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Madrigal Pharmaceuticals analyst ratings.
Discovering Madrigal Pharmaceuticals: A Closer Look
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
Madrigal Pharmaceuticals's Financial Performance
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Madrigal Pharmaceuticals's remarkable performance in 3M is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of 362.03%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Madrigal Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -39.75%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Madrigal Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -17.28%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Madrigal Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -9.6%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Madrigal Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of 0.55, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
How Are Analyst Ratings Determined?
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.